Skip to content
Colorectal Cancer Clinical Trials

Atlanta, Georgia

Colorectal cancer clinical trials in Atlanta, GA

39 colorectal cancer studies are recruiting participants at sites in Atlanta as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Atlanta at a glance

  • 39 studies are recruiting at a site in Atlanta.
  • By phase: Phase 1 (12), Phase 1/2 (5), Phase 2 (6), Phase 2/3 (2), Phase 3 (6), Phase 4 (2), No phase (3), Observational (3). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (25), university, hospital or other (13), government (1).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Atlanta

Basic details from each study's public record (the 30 most recently updated of 39). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT05863195 · updated
  2. A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    Erasca, Inc.
    Study site
    Emory University
    Registry record
    NCT06983743 · updated
  3. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Winship Cancer Institute at Emory University
    Registry record
    NCT07488676 · updated
  4. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Vividion Therapeutics, Inc.
    Study site
    Emory University School of Medicine
    Registry record
    NCT06004245 · updated
  5. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study site
    Winship Cancer Institute of Emory University
    Registry record
    NCT06270706 · updated
  6. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Piedmont Atlanta Hospital ( Site 2002)
    Registry record
    NCT06997497 · updated
  7. A Web-Based Dyadic Intervention for Colorectal Cancer

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Emory University
    Study site
    Emory University/Winship Cancer Institute
    Registry record
    NCT05663203 · updated
  8. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  9. FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Oncolytics Biotech
    Study site
    Emory Winship Cancer Institute
    Registry record
    NCT07446322 · updated
  10. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Northside Hospital
    Registry record
    NCT05174169 · updated
  11. A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Emory University
    Registry record
    NCT06400472 · updated
  12. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Wake Forest University Health Sciences
    Study site
    Northside Hospital
    Registry record
    NCT06418204 · updated
  13. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Emory University School of Medicine - Winship Cancer Institute
    Registry record
    NCT07114601 · updated
  14. Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Northside Hospital
    Registry record
    NCT07283939 · updated
  15. Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Emory Proton Therapy Center · Emory Saint Joseph's Hospital · Emory University Hospital Midtown
    Registry record
    NCT05673148 · updated
  16. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study sites
    Grady Memorial Hospital · Winship Cancer Institute Emory University
    Registry record
    NCT06662786 · updated
  17. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study sites
    Grady Memorial Hospital · Piedmont Cancer Institute · Winship Cancer Institute Emory University
    Registry record
    NCT06750094 · updated
  18. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    Emory University
    Registry record
    NCT03526835 · updated
  19. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Inc
    Study site
    Winship Cancer Institute at Emory University
    Registry record
    NCT07094204 · updated
  20. Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Buzzard Pharmaceuticals
    Study site
    Emory University
    Registry record
    NCT06634875 · updated
  21. A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Northside Hospital
    Registry record
    NCT07221357 · updated
  22. Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Emory University
    Study sites
    Emory Decatur Hospital · Emory Saint Joseph's Hospital · Emory University Hospital Midtown
    Registry record
    NCT07140679 · updated
  23. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EvolveImmune United, Inc
    Study site
    The Winship Cancer Institute Emory University
    Registry record
    NCT07217171 · updated
  24. Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT07147231 · updated
  25. Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

    • Phase 1
    • Ages 12 to 85
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Study site
    Emory University - Winship Cancer Institute
    Registry record
    NCT03715933 · updated
  26. A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Cartography Biosciences
    Study site
    Emory Winship Cancer Institute
    Registry record
    NCT07321106 · updated
  27. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    • Phase 1/2
    • From 12 months, up to 30 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Children's Healthcare of Atlanta - Arthur M Blank Hospital
    Registry record
    NCT04851119 · updated
  28. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Xencor, Inc.
    Study site
    Xencor Investigative Site
    Registry record
    NCT05433142 · updated
  29. AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Amgen
    Study site
    Emory University
    Registry record
    NCT07094113 · updated
  30. A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Coherus Oncology, Inc.
    Study site
    Winship Cancer Center - Emory University
    Registry record
    NCT06657144 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Atlanta, GA on ClinicalTrials.gov.

Ask about studies near Atlanta

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call